Published in J Chem Inf Model on August 23, 2010
Computational methods in drug discovery. Pharmacol Rev (2013) 1.51
Evaluation of model quality predictions in CASP9. Proteins (2011) 1.43
FRED and HYBRID docking performance on standardized datasets. J Comput Aided Mol Des (2012) 1.36
A force field with discrete displaceable waters and desolvation entropy for hydrated ligand docking. J Med Chem (2012) 1.08
Survey of public domain software for docking simulations and virtual screening. Hum Genomics (2011) 0.95
Docking challenge: protein sampling and molecular docking performance. J Chem Inf Model (2013) 0.89
A combination of receptor-based pharmacophore modeling & QM techniques for identification of human chymase inhibitors. PLoS One (2013) 0.80
A pose prediction approach based on ligand 3D shape similarity. J Comput Aided Mol Des (2016) 0.76
Structure-based ensemble-QSAR model: a novel approach to the study of the EGFR tyrosine kinase and its inhibitors. Acta Pharmacol Sin (2013) 0.75
Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS One (2014) 0.75
Best of both worlds: on the complementarity of ligand-based and structure-based virtual screening. J Chem Inf Model (2014) 0.75
Profiling the interaction mechanism of quinoline/quinazoline derivatives as MCHR1 antagonists: an in silico method. Int J Mol Sci (2014) 0.75
Ligand similarity guided receptor selection enhances docking accuracy and recall for non-nucleoside HIV reverse transcriptase inhibitors. J Mol Model (2015) 0.75
Molecular dynamics simulation and density functional theory studies on the active pocket for the binding of paclitaxel to tubulin. J Mol Model (2011) 0.75
Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov (2009) 4.16
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol (2008) 3.21
The vascular endothelium of the adipose tissue gives rise to both white and brown fat cells. Cell Metab (2012) 2.97
Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat Med (2002) 2.82
Crystal structure of the OXA-48 beta-lactamase reveals mechanistic diversity among class D carbapenemases. Chem Biol (2009) 1.93
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol (2008) 1.91
From cell-ECM interactions to tissue engineering. J Cell Physiol (2004) 1.91
Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One (2008) 1.90
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer (2005) 1.81
Leptin is induced in the ischemic cerebral cortex and exerts neuroprotection through NF-kappaB/c-Rel-dependent transcription. Stroke (2008) 1.72
Leptin signaling in breast cancer: an overview. J Cell Biochem (2008) 1.71
Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist (2006) 1.70
From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway. J Cell Biochem (2007) 1.65
Cell cycle regulation and neural differentiation. Oncogene (2003) 1.59
MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother (2011) 1.51
Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle (2009) 1.50
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res (2011) 1.48
Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. J Cell Physiol (2007) 1.47
Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia. Nat Clin Pract Cardiovasc Med (2008) 1.47
miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol (2013) 1.46
The occurrence of acute myocardial infarction in Italy: a five-year analysis of hospital discharge records. Aging Clin Exp Res (2010) 1.44
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol Ther (2010) 1.43
Wasting lives: the effects of toxic waste exposure on health. The case of Campania, Southern Italy. Cancer Biol Ther (2011) 1.42
Integrating role of T antigen, Rb2/p130, CTCF and BORIS in mediating non-canonical endoplasmic reticulum-dependent death pathways triggered by chronic ER stress in mouse medulloblastoma. Cell Cycle (2012) 1.41
Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer (2011) 1.39
The transcriptional co-activators CBP and p300 are activated via phenylephrine through the p42/p44 MAPK cascade. J Biol Chem (2001) 1.37
Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism. J Biol Chem (2005) 1.33
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget (2012) 1.33
Activation of MyoD-dependent transcription by cdk9/cyclin T2. Oncogene (2002) 1.33
Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle (2008) 1.32
Advantages and limitations of microarray technology in human cancer. Oncogene (2003) 1.30
Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res (2008) 1.30
Smart materials as scaffolds for tissue engineering. J Cell Physiol (2005) 1.30
Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem (2007) 1.26
In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget (2013) 1.26
Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J Med Chem (2011) 1.26
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res (2013) 1.23
CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. Proc Natl Acad Sci U S A (2010) 1.21
Lung Cancer: Are we up to the Challenge? Curr Genomics (2010) 1.21
Scaffold's surface geometry significantly affects human stem cell bone tissue engineering. J Cell Physiol (2008) 1.20
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype. Eur J Cancer (2011) 1.19
Inhibition of SNAP25 expression by HIV-1 Tat involves the activity of mir-128a. J Cell Physiol (2008) 1.19
Evidence for dysregulation of cell cycle by human polyomavirus, JCV, late auxiliary protein. Oncogene (2002) 1.19
Leptin increases axonal growth cone size in developing mouse cortical neurons by convergent signals inactivating glycogen synthase kinase-3beta. J Biol Chem (2006) 1.18
pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer. Oncogene (2003) 1.17
Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene (2004) 1.16
The gap between the physiological and therapeutic roles of mesenchymal stem cells. Med Res Rev (2014) 1.15
Involvement of polyamine oxidase in wound healing. Plant Physiol (2007) 1.11
CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation. J Pathol (2004) 1.11
Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. J Cell Biochem (2005) 1.10
Emerging roles of DNA tumor viruses in cell proliferation: new insights into genomic instability. Oncogene (2003) 1.08
Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res (2004) 1.08
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget (2014) 1.07
Discovery of new therapeutic targets by the informational spectrum method. Curr Protein Pept Sci (2008) 1.06
Characterization of a novel peripheral pro-lipolytic mechanism in mice: role of VGF-derived peptide TLQP-21. Biochem J (2012) 1.06
Deacetylase recruitment by the C/H3 domain of the acetyltransferase p300. Oncogene (2004) 1.06
miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle (2013) 1.06
The tumor suppressor role of CTCF. J Cell Physiol (2012) 1.06
Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. J Med Chem (2006) 1.05
In vivo phenotyping of the ob/ob mouse by magnetic resonance imaging and 1H-magnetic resonance spectroscopy. Obesity (Silver Spring) (2006) 1.05
Human polyomaviruses and brain tumors. Brain Res Brain Res Rev (2005) 1.04
In vitro senescence of rat mesenchymal stem cells is accompanied by downregulation of stemness-related and DNA damage repair genes. Stem Cells Dev (2009) 1.03
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol (2014) 1.02
Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J Cell Physiol (2007) 1.02
Cdk9 phosphorylates p53 on serine 392 independently of CKII. J Cell Physiol (2006) 1.02
The retinoblastoma family: twins or distant cousins? Genome Biol (2002) 1.02
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. J Cell Physiol (2014) 1.02
Sensory or sympathetic white adipose tissue denervation differentially affects depot growth and cellularity. Am J Physiol Regul Integr Comp Physiol (2004) 1.02
The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies. FEBS J (2006) 1.02
Novel dual Src/Abl inhibitors for hematologic and solid malignancies. Expert Opin Investig Drugs (2010) 1.02
Incidence of breast cancer in Italy: mastectomies and quadrantectomies performed between 2000 and 2005. J Exp Clin Cancer Res (2009) 1.02
Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer (2008) 1.01
Analysis of a mutant p53 protein arising in a medulloblastoma from a mouse transgenic for the JC virus early region. Anticancer Res (2007) 1.01
Guanylated diamines, triamines, and polyamines: chemistry and biological properties. Chem Rev (2011) 1.01
Brg1 chromatin remodeling factor is involved in cell growth arrest, apoptosis and senescence of rat mesenchymal stem cells. J Cell Sci (2007) 1.01
Reversible transdifferentiation of secretory epithelial cells into adipocytes in the mammary gland. Proc Natl Acad Sci U S A (2004) 1.01
Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol (2005) 1.00
Indoles and related compounds as cannabinoid ligands. Mini Rev Med Chem (2008) 1.00
Bartonella: emerging pathogen or emerging awareness? Int J Infect Dis (2008) 0.99
Synthesis, antifungal activity, and molecular modeling studies of new inverted oxime ethers of oxiconazole. J Med Chem (2002) 0.99
Silencing of RB1 but not of RB2/P130 induces cellular senescence and impairs the differentiation potential of human mesenchymal stem cells. Cell Mol Life Sci (2013) 0.99
Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitors. Bioorg Med Chem Lett (2012) 0.98
Proposal of a new binding orientation for non-peptide AT1 antagonists: homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis. J Med Chem (2006) 0.98
CDK9: from basal transcription to cancer and AIDS. Cancer Biol Ther (2002) 0.98
Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. Oncogene (2003) 0.97
Electromagnetic fields at mobile phone frequency induce apoptosis and inactivation of the multi-chaperone complex in human epidermoid cancer cells. J Cell Physiol (2005) 0.97
Epigenetic modulation of estrogen receptor-alpha by pRb family proteins: a novel mechanism in breast cancer. Cancer Res (2007) 0.97
Lennard-Jones potential and dummy atom settings to overcome the AUTODOCK limitation in treating flexible ring systems. J Chem Inf Model (2007) 0.97
NSP 5a3a: a potential novel cancer target in head and neck carcinoma. Oncotarget (2010) 0.97
CL316,243 and cold stress induce heterogeneous expression of UCP1 mRNA and protein in rodent brown adipocytes. J Histochem Cytochem (2002) 0.96
Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-candida activity, and quantitative structure-analysis relationship studies. J Med Chem (2002) 0.96
Emerging roles of RB family: new defense mechanisms against tumor progression. J Cell Physiol (2013) 0.96
JC virus large T-antigen and IGF-I signaling system merge to affect DNA repair and genomic integrity. J Cell Physiol (2006) 0.96
Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells. J Biol Chem (2006) 0.96
Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives. J Med Chem (2004) 0.96
Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors. Blood (2007) 0.96
Mosaic analysis of insulin receptor function. J Clin Invest (2004) 0.95
Physical interaction between pRb and cdk9/cyclinT2 complex. Oncogene (2002) 0.95
Interplay between cdk9 and NF-kappaB factors determines the level of HIV-1 gene transcription in astrocytic cells. Oncogene (2002) 0.95